Adolescent non‐Hodgkin lymphoma and Hodgkin lymphoma: state of the science
Open Access
- 9 December 2008
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 144 (1) , 24-40
Abstract
Summary: Lymphoma is the most common malignancy among adolescents, accounting for >25% of newly diagnosed cancers in the 15–19 year age group. Hodgkin lymphoma (HL) accounts for the majority (two‐thirds) of cases, while the remainder of patients have one of four subtypes of non‐Hodgkin lymphoma (NHL): diffuse large B‐cell lymphoma (DLBCL) including primary mediastinal B‐cell lymphoma (PMBL), Burkitt lymphoma (BL), lymphoblastic lymphoma (LL) or anaplastic large cell lymphoma (ALCL). Epidemiology, histology, treatment and outcome differ between HL and NHL, as well as among the various subtypes of NHL. Adolescent lymphoma is particularly interesting because it often shares features with both childhood and adult lymphoma. As medical oncologists and paediatric oncologists often follow divergent treatment plans, disagreements may arise between practitioners as to how best treat the adolescent group. Additional complicating factors associated with the adolescent years, such as lack of insurance, issues pertaining to body image, and concerns about fertility, can also hinder prompt, appropriate medical management. This review details the complexities associated with the diagnosis and treatment of adolescent lymphoma and updates the state of the science, with particular emphasis on epidemiology, diagnosis, and proper management of HL and the various subtypes of NHL.Keywords
This publication has 102 references indexed in Scilit:
- What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesBlood, 2008
- Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center BiomarkersJournal of Clinical Oncology, 2008
- Pediatric diffuse large B‐cell lymphoma demonstrates a high proliferation index, frequent c‐Myc protein expression, and a high incidence of germinal center subtype: Report of the French–American–British (FAB) international study groupPediatric Blood & Cancer, 2008
- Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor StudyBlood, 2008
- Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup studyBlood, 2008
- Contribution of the Epstein–Barr virus to the molecular pathogenesis of Hodgkin lymphomaJournal of Clinical Pathology, 2007
- Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescentsBlood, 2006
- Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patientsBlood, 2006
- Acute Myeloid Leukemia Following Hodgkin Lymphoma: A Population-Based Study of 35 511 PatientsJNCI: Journal of the National Cancer Institute, 2006
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000